A recent guidance on managing ‘type 1 and type 2 diabetes in COVID-19 patients’ (https://abcd.care/resource/concise-advice-inpatient-diabetes-during-covid19-front-door-guidance), advises stopping Dipeptidyl peptidase-4 (DPP4) inhibitors in patients with type 2 diabetes with an acute COVID-19 infection. The gene discussed is DPP4; the disease is COVID-19.